Ironwood Pharmaceuticals

Last updated
Ironwood Pharmaceuticals, Inc
Type Public
Nasdaq:  IRWD (Class A)
Russell 2000 Component
S&P 600 component
Founded1998
HeadquartersBoston, Massachusetts.
Website www.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. [1] [2] In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, [3] which at the time were focused on identifying small molecules that could inhibit fungal invasins, [3] [4] along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, [1] and also Richard Bailey, who had run Monsanto's nutritional business. [2] Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. [5] [6]

By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. [1] By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development. [2] Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006. [2] Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia. [7]

By 2009, Ironwood had raised a total of $281M. [2] In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14. [8] Later that year it sold its interests in Microbia to DSM for an undisclosed sum. [9]

Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere), [10] a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012. [11] [12] Most of the marketing rights were licensed to Allergan and Astellas. [13] [14] [15]

It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016. [16]

BNC210 is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned. [17]

In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board. [18]

Related Research Articles

Alosetron Medication

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only.

Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis.

Rifaximin Antibiotic medication

Rifaximin, sold under the brand name Xifaxan and Zaxine (Canada) among others, is an antibiotic medication used to treat travelers' diarrhea, irritable bowel syndrome, and hepatic encephalopathy. It has poor absorption when taken by mouth.

Olsalazine

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Lubiprostone Medication used for constipation

Lubiprostone is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

Rose Pharma is a private company that was founded in 2003 as Gastrotech Pharma and is located in Copenhagen, Denmark. The company is led by CEO Leif Helth Jensen, who is, together with Michael Forer and Florian Schönharting, also member of the Board of Directors. Rose Pharma is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

The magainins are a class of antimicrobial peptides found in the African clawed frog. The peptides are cationic, generally lack a stable conformation in water but form amphipathic α-helix in membranes; their mechanism against micro-organisms is unclear but they disrupt the cell membranes of a broad spectrum of bacteria, protozoa, and fungi.

Nathaniel David American scientist and entrepreneur

Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx, Achaogen, Kythera Biopharmaceuticals, Sapphire Energy and Unity Biotechnology. These companies have collectively raised more than $1.5 billion in financing.

BNC-210 Chemical compound

BNC210 is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials.

Linaclotide Medicine

Linaclotide, is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others are gastrointestinal.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Relamorelin

Relamorelin is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics. In humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels, and, like other GHSR agonists, increases appetite. As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation. The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Plecanatide, sold under the brand name Trulance, is a medication for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. Plecanatide is an agonist of guanylate cyclase-C. Plecanatide increases intestinal transit and fluid through a buildup of cGMP.

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

Solriamfetol Medication used for the treatment of excessive sleepiness

Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.

John J. Talley is an American medicinal chemist who was the lead chemist in the discovery of the COX-2 selective nonsteroidal anti-inflammatory drug celecoxib and a co-inventor of amprenavir, a protease inhibitor used to treat HIV infection.

References

  1. 1 2 3 Withers, Melissa (September 22, 2004). "Drug hunters". Paradigm Magazine, Whitehead Institute.
  2. 1 2 3 4 5 Timmerman, Luke (23 February 2009). "Xconomy: Renewables Aren't Just for Biofuels: Microbia Makes Industrial Chemicals a Bit Greener". Xconomy.
  3. 1 2 Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. ↑ McCarthy, Alice A. (February 2003). "Microbia" (PDF). Chemistry & Biology. 10 (2): 99–100. doi: 10.1016/S1074-5521(03)00031-0 . PMID   12618178.
  5. ↑ Hornby, PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–24. doi:10.1517/17460441.2015.1049528. PMID   26193876. S2CID   207494271.
  6. ↑ "Director profile: Mark Currie, Ph.D." MUSC Foundation for Research Development. Retrieved 15 April 2018.
  7. ↑ "Microbia Announces Name Change to Ironwood Pharmaceuticals".
  8. ↑ "Ironwood's I.P.O. Disappoints". New York Times DealBook. February 4, 2010.
  9. ↑ McBride, Ryan (22 September 2010). "Ironwood Pharmaceuticals Sells Struggling Microbia Subsidiary to Royal DSM". Xconomy.
  10. ↑ "Linaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  11. ↑ "US label for linaclotide" (PDF). FDA. January 2017. Retrieved 15 April 2018. For label updates see FDA index page for NDA 202811
  12. ↑ "UK label: Linaclotide Summary of Product Characteristics". Electronic Medicines Compendium. September 2017. Retrieved 15 April 2018.
  13. ↑ Nocera, Joe (9 January 2018). "How Allergan Continues to Make Drug Prices Insane". Bloomberg News.
  14. ↑ Jones, Stacy; Burdette, kacy; Wieczner, Jen (July 30, 2015). "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune.
  15. ↑ "8-K" (PDF). Ironwood. 31 January 2017.
  16. ↑ "Recanaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  17. ↑ "BNC 210". AdisInsight. Retrieved 15 April 2018.
  18. ↑ Tirrell, Meg (2018-04-09). "Biotech activist Alex Denner's next target: Ironwood Pharma". CNBC. Retrieved 2018-05-03.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.